期刊文献+

HLA配型不合造血干细胞移植GIAC方案100例临床分析 被引量:68

Mismatched hematopoietic stem cell transplantation using GIAC protocol: report of 100 cases
原文传递
导出
摘要 目的 研究人类白细胞抗原 (HLA)配型不合造血干细胞移植 (HSCT)治疗恶性血液病的新移植方案。方法  10 0例恶性血液病患者 ,5 6例为高危病例 ,进行HLA配型至少 1个位点不合的亲缘供者HSCT。采用GIAC移植方案 ,即G CSF动员供者干细胞 ,强化、延长的免疫抑制促进植入及预防移植物抗宿主病 (GVHD) ,使用抗胸腺细胞球蛋白 ,以及骨髓及外周血干细胞联合移植。结果 所有患者均达完全供者植入。发生Ⅱ~Ⅳ度急性GVHD(aGVHD) 4 5例 ,累积发生率 4 8.39% ,发生Ⅲ~Ⅳ度aGVHD 12例 ,累积发生率 12 .90 %。 6 1例可评估的患者中 ,发生慢性 (c)GVHD 38例 ,广泛型 11例。复发 12例 ,11例为高危患者 ,3例经供者淋巴细胞输注达再次完全缓解。死亡 2 2例 ,6例死于复发 ,16例死于移植相关合并症。 72例患者无病存活 ,1年预期无病生存率 ,高危组为 (4 7.6 3± 8.4 9) % ,标危组为 (83.5 2± 7.4 1) %。结论 GIAC方案适用于HLA配型不合的HSCT ,是治疗恶性血液病比较安全。 Objective To explore the clinical application of human leukocyte antigen(HLA) mismatched hematopoietic stem cell transplantation(HSCT) for malignant hematological diseases using a new GIAC protocol. Methods One hundred patients with malignant hematological disease received G-CSF mobilization, intensive immunosuppression, ATG and combination of bone marrow and peripheral blood stem cell transplantation at least 1 locus mis-matched hematopoietic stem cell transplant performed with GIAC protocol. The conditioning regimen was intensified and prolonged with combined use of CsA, MMF and ATG for GVHD prophylaxis. Results All patients achieved sustained, full donor-type engraftment. The cumulative incidence of grade Ⅱ~Ⅳ aGVHD was 48.39%,and grade Ⅲ~Ⅳ aGVHD was 12.90%. Thirty-eight patients had cGVHDs which were of extensive type in 11 patients. Twelve patients relapsed, 11 of them were high-risk patients, and 3 returned to CR after donor lymphocyte infusion. Twenty-two patients died, owing to recurrent diseases in 6 and transplant-related complications in 16 cases. Seventy-two patients were alive and disease free, with 1 year disease-free survival probabilities for standard and high risk patients of (83.52±7.41)% and (47.63±8.49)%, respectively. Conclusion The GIAC protocol for at least 1 locus mismatched hematopoietic stem cell transplantation is relatively safe and efficient for patients with hematological malignancies.
出处 《中华血液学杂志》 CAS CSCD 北大核心 2004年第8期453-457,共5页 Chinese Journal of Hematology
关键词 HLA配型 造血干细胞 细胞移植 GIAC方案 组织相容性试验 粒细胞集落刺激因子 HSCT Histocompatibility testing mismatched Granulocyte colony stimulating factor Hematopoietic stem cell transplantation Graft-versus-host disease
  • 相关文献

参考文献12

  • 1Kernan NA, Bartsch G, Ash RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med, 1993, 328: 593-602.
  • 2Beatty PG. Marrow transplantation using volunteer unrelated donors in a comparison of mismatched family donor transplants:a Seattle perspective. Bone Marrow Transplant, 1994, 14 Suppl 4: S39-41.
  • 3Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med,1998, 339: 1186-1193.
  • 4Mineishi S, Longo WL, Atkinson ME, et al. Addition of highdose Ara-C to the BMT conditioning regimen reduces leukemia relapse without an increase in toxicity. Bone Marrow Transplant, 1999, 23: 1217-1222.
  • 5Hassan HT,Stockschlader M,Schleimer B,et al. Comparison of the content and subpopulation of CD3 and CD34 positive cells in bone marrow harvest and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors. Transplant Immunol, 1996,
  • 6Mielcarek M, Roecklein BA, Torok-Storb B. CD14+- cells in GCSF mobilized peripheral blood mononuclear cells induce secretion of interleukin-6 and G-CSF by marrow stroma. Blood,1996, 87: 574-580.
  • 7Pan L, Delmonte J Jr, Jalonen CK, et al. Pretreatment of donor mice with granulocyte-colony stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood, 1995,86 :
  • 8Arpinati M, Loken M, Anasetti C. G-CSF mobilizes type 2-derdritic cells rather than type 1-dendritic cells. Blood, 1998, 92Suppl 1: 111a.
  • 9Ji SQ, Chen HR, Wang HX, et al. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia. Biol Blood Marrow Tran
  • 10Ji SQ, Chen HR, Xun CQ, et al. The effect of G-CSF stimulated donor marrow on engraftment and incidence of graft-versushost disease in allogeneic bone marrow transplantation. Clin Transplant, 2001, 15: 317-323.

同被引文献720

引证文献68

二级引证文献227

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部